Immunomodulatory role of PPAR-γ in alveolar macrophages

Journal of Investigative Medicine

Volumn 56, Issue 2, 2008, Pages 522-527

  Reddy, Raju C ^a  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

Alveolar macrophage; Inflammation; PPAR

Indexed keywords

AUTACOID; CD36 ANTIGEN; FATTY ACID; FC RECEPTOR; IMMUNOGLOBULIN G; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; IMMUNOLOGIC FACTOR;

ADAPTIVE IMMUNITY; ANTIGEN PRESENTATION; ASTHMA; ENZYME ACTIVATION; GENE EXPRESSION; HUMAN; HUMORAL IMMUNITY; IMMUNOMODULATION; IMMUNOSTIMULATION; INFLAMMATION; INNATE IMMUNITY; LUNG ALVEOLUS; LUNG ALVEOLUS PROTEINOSIS; LUNG DISEASE; LUNG INJURY; LUNG SARCOIDOSIS; MACROPHAGE; NONHUMAN; PHAGOCYTOSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; IMMUNOLOGY; LUNG ALVEOLUS MACROPHAGE; PNEUMONIA;

HUMANS; IMMUNOLOGIC FACTORS; MACROPHAGES, ALVEOLAR; PNEUMONIA; PPAR GAMMA;

EID: 70349239310     PISSN: 17088267     EISSN: None     Source Type: Journal    
DOI: 10.2310/JIM.0b013e3181659972     Document Type: Review

References (49)

1. Feige JN, Gelman L, Tudor C, et al. Fluorescence imaging reveals the nuclear behavior of peroxisome proliferator-activated receptor/retinoid X receptor heterodimers in the absence and presence of ligand. J Biol Chem. 2005;280:17880-17890.
2. Glass CK, Ogawa S. Combinatorial roles of nuclear receptors in inflammation and immunity. Nat Rev Immunol. 2006;6:44-55.
3. Tontonoz P, Nagy L, Alvarez JGA, et al. PPAR+ promotes monocyte/macrophage differentiation and uptake of oxidized LDL. Cell. 1998;93:241-252.
4. Nagy L, Tontonoz P, Alvarez JG, et al. Oxidized LDL regulates macrophage gene expression through ligand activation of PPAR. Cell. 1998;93:229-240.
5. Chinetti G, Griglio S, Antonucci M, et al. Activation of proliferator-activated receptors α and γ induces apoptosis of human monocyte-derived macrophages. J Biol Chem. 1998;273:25573-25580.
6. Thomas ED, Ramberg RE, Sale GE, et al. Direct evidence for a bone marrow origin of the alveolar macrophage in man. Science. 1976;192:1016-1018.
7. Bitterman PB, Saltzman LE, Adelberg S, et al. Alveolar macrophage replication. One mechanism for the expansion of the mononuclear phagocyte population in the chronically inflamed lung. J Clin Invest. 1984;74:460-469.
8. Smith MR, Standiford TJ, Reddy RC. PPARs in Alveolar Macrophage Biology. PPAR Res. 2007;2007:23812.
9. Twigg HL. Macrophages in innate and acquired immunity. Semin Respir Crit Care Med. 2004;25:21-31.
10. Takabayshi K, Corr M, Hayashi T, et al. Induction of a homeostatic circuit in lung tissue by microbial compounds. Immunity. 2006;24:475-487.
11. Martin TR, Raugi G, Merritt TL, et al. Relative contribution of leukotriene B4 to the neutrophil chemotactic activity produced by the resident human alveolar macrophage. J Clin Invest. 1987;80:1114-1124.
12. Carré PC, Mortenson RL, King TE Jr, et al. Increased expression of the interleukin-8 gene by alveolar macrophages in idiopathic pulmonary fibrosis. A potential mechanism for the recruitment and activation of neutrophils in lung fibrosis. J Clin Invest. 1991;88:1802-1810.
13. Smith RE, Strieter RM, Zhang K, et al. A role for C-C chemokines in fibrotic lung disease. J Leukoc Biol. 1995; 57:782-787.
14. Standiford TJ, Rolfe MW, Kunkel SL, et al. Macrophage inflammatory protein-1 α expression in interstitial lung disease. J Immunol. 1993;151:2852-2863.
15. Kawabe T, Isobe KI, Hasegawa Y, et al. Immunosuppressive activity induced by nitric oxide in culture supernatant of activated rat alveolar macrophages. Immunology. 1992; 76:72-78.
16. Roth MD, Golub SH. Human pulmonary macrophages utilize prostaglandins and transforming growth factor "1 to suppress lymphocyte activation. J Leukoc Biol. 1993;53:366-371.
17. Gordon S. Alternative activation of macrophages. Nat Rev Immunol. 2003;3:23-35.
18. Mantovani A, Sica A, Sozzani S, et al. The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol. 2004;25:677-686.
19. Holt PG, Oliver J, Bilyk N, et al. Downregulation of the antigen presenting cell function(s) of pulmonary dendritic cells in vivo by resident alveolar macrophages. J Exp Med. 1993;177:397-407.
20. Thepen T, Kraal G, Holt PG. The role of alveolar macrophages in regulation of lung inflammation. Ann N Y Acad Sci. 1994;725:200-206.
21. Asada K, Sasaki S, Suda T, et al. Antiinflammatory roles of peroxisome proliferator-activated receptor + in human alveolar macrophages. Am J Respir Crit Care Med. 2004; 169:195-200.
22. Reddy RC, Keshamouni VG, Jaigirdar SH, et al. Deactivation of murine alveolar macrophages by peroxisome proliferator-activated receptor peroxisome proliferator-activated receptor + ligands. Am J Physiol Lung Cell Mol Physiol. 2004;286:L613-L619.
23. Ricote M, Li AC, Willson TM, et al. The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation. Nature. 1998;391:79-82.
24. Baker PRS, Lin Y, Schopfer FJ, et al. Fatty acid transduction of nitric oxide signaling: multiple nitrated unsaturated fatty acid derivatives exist in human blood and urine and serve as endogenous peroxisome proliferator-activated receptor ligands. J Biol Chem. 2005;280: 42464-42475.
25. Coles B, Bloodsworth A, Clark SR, et al. Nitrolinoleate inhibits superoxide generation, degranulation, and integrin expression by human neutrophils: novel antiinflammatory properties of nitric oxide-derived reactive species in vascular cells. Circ Res. 2002;91:375-381.
26. Bell-Parikh LC, Ide T, Lawson JA, et al. Biosynthesis of 15-deoxy-Δ12,14-PGJ2 and the ligation of PPARγ. J Clin Invest. 2003;112:945-955.
27. Cui T, Schopfer FJ, Zhang J, et al. Nitrated fatty acids: endogenous anti-inflammatory signaling mediators. J Biol Chem. 2006;281:35686-35698.
28. Lian X, Yan C, Qin Y, et al. Neutral lipids and peroxisome proliferator-activated receptor-γ control pulmonary gene expression and inflammation-triggered pathogenesis in lysosomal acid lipase knockout mice. Am J Pathol. 2005; 167:813-821.
29. -/-mice. Am J Pathol. 2006; 169:916-926.
30. Alaoui-El-Azher M, Wu Y, Havet N, et al. Arachidonic acid differentially affects basal and lipopolysaccharideinduced sPLA2-IIA expression in alveolar macrophages through NF-κB and PPAR-γ-dependent pathways. Mol Pharmacol. 2002;61:786-794.
31. Becker J, Delayre-Orthez C, Frossard N, et al. Regulation of inflammation by PPARs: a future approach to treat lung inflammatory diseases? Fundam Clin Pharmacol. 2006; 20:429-447.
32. Yan C, Du H. Alveolus formation: what have we learned from genetic studies? J Appl Physiol. 2004;97:1543Y1548.
33. Culver DA, Barna BP, Raychaudhuri B, et al. Peroxisome proliferator-activated receptor γ activity is deficient in alveolar macrophages in pulmonary sarcoidosis. Am J Respir Cell Mol Biol. 2004;30:1-5.
34. Baughman RP, Teirstein AS, Judson MA, et al. Clinical characteristics of patients in a case control study of sarcoidosis. Am J Respir Crit Care Med. 2001;164:1885-1889.
35. Zissel G, Prasse A, Muller-Quernheim J. SarcoidosisV immunopathogenetic concepts. Semin Respir Crit Care Med. 2007;28:3-14.
36. Hunninghake GW, Bedell GN, Zavala DC, et al. Role of interleukin-2 release by lung T-cells in active pulmonary sarcoidosis. Am Rev Respir Dis. 1983;128:634-638.
37. Shigehara K, Shijubo N, Ohmichi M, et al. IL-12 and IL-18 are increased and stimulate IFN-γ production in sarcoid lungs. J Immunol. 2001;166:642-649.
38. Seymour JF, Presneill JJ. Pulmonary alveolar proteinosis: progress in the first 44 years. Am J Respir Crit Care Med. 2002;166:215-235.
39. Golde DW, Territo M, Finley TN, et al. Defective lung macrophages in pulmonary alveolar proteinosis. Ann Intern Med. 1976;85:304-309.
40. Tanaka N, Watanabe J, Kitamura T, et al. Lungs of patients with idiopathic pulmonary alveolar proteinosis express a factor which neutralizes granulocyte-macrophage colony stimulating factor. FEBS Lett. 1999;442:246-250.
41. Kavuru MS, Sullivan EJ, Piccin R, et al. Exogenous granulocyte-macrophage colony-stimulating factor administration for pulmonary alveolar proteinosis. Am J Respir Crit Care Med. 2000;161:1143-1148.
42. Seymour JF, Presneill JJ, Schoch OD, et al. Therapeutic efficacy of granulocyte-macrophage colony-stimulating factor in patients with idiopathic acquired alveolar proteinosis. Am J Respir Crit Care Med. 2001;163: 524-531.
43. Bonfield TL, Farver CF, Barna BP, et al. Peroxisome proliferator- activated receptor-γ is deficient in alveolar macrophages from patients with alveolar proteinosis. Am J Respir Cell Mol Biol. 2003;29:677-682.
44. Huang JT, Welch JS, Ricote M, et al. Interleukin- 4-dependent production of PPAR-γ ligands in macrophages by 12/15-lipoxygenase. Nature. 1999;400: 378-382.
45. Christensen PJ, Goodman RE, Pastoriza L, et al. Induction of lung fibrosis in the mouse by intratracheal instillation of fluorescein isothiocyanate is not T-cell-dependent. Am J Pathol. 1999;155:1773-1779.
46. Standiford TJ, Keshamouni VG, Reddy RC. Peroxisome proliferator-activated receptor-γ as a regulator of lung inflammation and repair. Proc Am Thorac Soc. 2005;2: 226-231.
47. Tang C, Inman MD, van Rooijen N, et al. Th type 1-stimulating activity of lung macrophages inhibits Th2-mediated allergic airway inflammation by an IFN-γ-dependent mechanism. J Immunol. 2001;166:1471-1481.
48. Peters-Golden M. The alveolar macrophage: the forgotten cell in asthma. Am J Respir Cell Mol Biol. 2004;31:3-7.
49. Kobayashi M, Thomassen MJ, Rambasek T, et al. An inverse relationship between peroxisome proliferator-activated receptor γ and allergic airway inflammation in an allergen challenge model. Ann Allergy Asthma Immunol. 2005;95:468-473.